Technical Analysis for SHPG - Shire plc

Grade Last Price % Change Price Change
grade A 179.2 0.00% 0.00
SHPG closed up 4.1 percent on Friday, January 4, 2019, on 2.76 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical SHPG trend table...

Date Alert Name Type % Chg
Jan 4 Crossed Above 50 DMA Bullish 0.00%
Jan 4 Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Jan 4 Multiple of Ten Bearish Other 0.00%
Jan 4 Above Upper BB Strength 0.00%
Jan 4 Gapped Up Strength 0.00%
Jan 4 Upper Bollinger Band Touch Strength 0.00%
Jan 3 20 DMA Support Bullish 4.10%
Jan 2 20 DMA Support Bullish 3.76%
Dec 31 Narrow Range Bar Range Contraction 2.96%
Dec 31 NR7 Range Contraction 2.96%

Older signals for SHPG ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). The SP segment offers products for the treatment of attention deficit and hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. The HGT segment offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. The RM segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of behavioral health, gastrointestinal, HGT, RM, and other therapeutic areas. The company markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. It has operations in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.
Biopharmaceutical Alpha Drugs Pharmaceutical Products Dialysis Regenerative Medicine Ulcerative Colitis Psychoactive Drugs Hereditary Angioedema Adhd Amphetamine Fabry Disease Gaucher Disease Hyperactivity Disorder Methylphenidate Nootropics Treatment Of Fabry Disease Essential Thrombocythemia Phenethylamines Stimulants Taar1 Agonists Thrombocythemia
Is SHPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 182.47
52 Week Low 122.9082
Average Volume 1,927,639
200-Day Moving Average 168.5041
50-Day Moving Average 174.9524
20-Day Moving Average 172.5045
10-Day Moving Average 173.028
Average True Range 3.6272
ADX 12.2
+DI 37.3948
-DI 23.041
Chandelier Exit (Long, 3 ATRs ) 170.3384
Chandelier Exit (Short, 3 ATRs ) 176.1716
Upper Bollinger Band 178.8874
Lower Bollinger Band 166.1216
Percent B (%b) 1.02
BandWidth 7.400271
MACD Line -0.0034
MACD Signal Line -0.7568
MACD Histogram 0.7535
Fundamentals Value
Market Cap 53.38 Billion
Num Shares 298 Million
EPS 2.23
Price-to-Earnings (P/E) Ratio 80.36
Price-to-Sales 2.82
Price-to-Book 1.34
PEG Ratio 0.84
Dividend 0.92
Dividend Yield 0.51%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 187.47
Resistance 3 (R3) 187.22 184.22 186.09
Resistance 2 (R2) 184.22 182.12 184.34 185.63
Resistance 1 (R1) 181.71 180.81 182.97 181.96 185.17
Pivot Point 178.71 178.71 179.34 178.83 178.71
Support 1 (S1) 176.20 176.61 177.46 176.45 173.23
Support 2 (S2) 173.20 175.30 173.32 172.77
Support 3 (S3) 170.69 173.20 172.31
Support 4 (S4) 170.94